Aptalis Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aptalis Pharma Inc.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
Nasdaq, Hong Kong and soon Shanghai, major Chinese firm BeiGene will be listed on three stock markets globally. But the high offer price of its imminent debut on China's STAR Market has raised concern among some investments and involved the use of a rare mechanism in the country.
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
- Other Names / Subsidiaries
- Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.